JP5138932B2 - モダフィニルの改変された放出の製薬学的組成物 - Google Patents

モダフィニルの改変された放出の製薬学的組成物

Info

Publication number
JP5138932B2
JP5138932B2 JP2006527123A JP2006527123A JP5138932B2 JP 5138932 B2 JP5138932 B2 JP 5138932B2 JP 2006527123 A JP2006527123 A JP 2006527123A JP 2006527123 A JP2006527123 A JP 2006527123A JP 5138932 B2 JP5138932 B2 JP 5138932B2
Authority
JP
Japan
Prior art keywords
modafinil
pharmaceutical composition
composition according
release
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006527123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007518696A (ja
JP2007518696A5 (https=
Inventor
パリク，アルパ
パテル，ピユシユ・アール
Original Assignee
セフアロン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34381093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5138932(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セフアロン・インコーポレーテツド filed Critical セフアロン・インコーポレーテツド
Publication of JP2007518696A publication Critical patent/JP2007518696A/ja
Publication of JP2007518696A5 publication Critical patent/JP2007518696A5/ja
Application granted granted Critical
Publication of JP5138932B2 publication Critical patent/JP5138932B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2006527123A 2003-09-18 2004-09-20 モダフィニルの改変された放出の製薬学的組成物 Expired - Fee Related JP5138932B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50402803P 2003-09-18 2003-09-18
US60/504,028 2003-09-18
US10/944,528 US8153159B2 (en) 2003-09-18 2004-09-17 Modafinil modified release pharmaceutical compositions
US10/944,528 2004-09-17
PCT/US2004/030815 WO2005027890A1 (en) 2003-09-18 2004-09-20 Modafinil modified release pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2007518696A JP2007518696A (ja) 2007-07-12
JP2007518696A5 JP2007518696A5 (https=) 2007-11-01
JP5138932B2 true JP5138932B2 (ja) 2013-02-06

Family

ID=34381093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527123A Expired - Fee Related JP5138932B2 (ja) 2003-09-18 2004-09-20 モダフィニルの改変された放出の製薬学的組成物

Country Status (20)

Country Link
US (1) US8153159B2 (https=)
EP (1) EP1670447B1 (https=)
JP (1) JP5138932B2 (https=)
KR (1) KR20060117910A (https=)
AR (1) AR046410A1 (https=)
AT (1) ATE448780T1 (https=)
AU (1) AU2004274017B2 (https=)
BR (1) BRPI0414299A (https=)
CA (1) CA2536666C (https=)
DE (1) DE602004024220D1 (https=)
EA (1) EA011400B1 (https=)
ES (1) ES2336215T3 (https=)
IL (1) IL173738A (https=)
IS (1) IS2787B (https=)
MX (1) MXPA06003125A (https=)
MY (1) MY144755A (https=)
NO (1) NO20060964L (https=)
NZ (1) NZ545573A (https=)
TW (1) TWI344840B (https=)
WO (1) WO2005027890A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
EP1755388B1 (en) * 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
AU2007214487A1 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20090082461A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched modafinil
JP5250285B2 (ja) * 2008-03-26 2013-07-31 富士フイルム株式会社 経口物用被覆材、可食性容器およびそれらを用いた経口物
WO2010012407A1 (en) * 2008-07-29 2010-02-04 Ashland Licensing And Intellectual Property Llc. Modified additives for suppressing dust formation
KR101465077B1 (ko) * 2010-07-06 2014-11-26 주식회사 네비팜 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
EP3137060B2 (en) 2014-05-01 2023-12-20 Sun Pharmaceutical Industries Ltd Extended release suspension compositions
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
BR112020000318A2 (pt) * 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
ATE357228T1 (de) 2001-05-25 2007-04-15 Cephalon Inc Feste pharmazeutische formulierung enthaltend modafinil
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Also Published As

Publication number Publication date
EP1670447A1 (en) 2006-06-21
IL173738A0 (en) 2006-07-05
ES2336215T3 (es) 2010-04-09
EA011400B1 (ru) 2009-02-27
IL173738A (en) 2012-07-31
TW200520748A (en) 2005-07-01
WO2005027890A1 (en) 2005-03-31
DE602004024220D1 (de) 2009-12-31
AR046410A1 (es) 2005-12-07
IS2787B (is) 2012-06-15
EA200600590A1 (ru) 2006-08-25
US8153159B2 (en) 2012-04-10
AU2004274017A1 (en) 2005-03-31
ATE448780T1 (de) 2009-12-15
NO20060964L (no) 2006-04-18
NZ545573A (en) 2010-02-26
US20050095294A1 (en) 2005-05-05
MY144755A (en) 2011-10-31
KR20060117910A (ko) 2006-11-17
TWI344840B (en) 2011-07-11
HK1089697A1 (en) 2006-12-08
JP2007518696A (ja) 2007-07-12
EP1670447B1 (en) 2009-11-18
CA2536666A1 (en) 2005-03-31
AU2004274017B2 (en) 2010-07-08
MXPA06003125A (es) 2006-06-20
CA2536666C (en) 2012-06-19
BRPI0414299A (pt) 2006-11-14
IS8327A (is) 2006-02-23

Similar Documents

Publication Publication Date Title
AU2011222856B2 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
EP1940361B1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20190054009A1 (en) Daily formulation of lacosamide
KR102408292B1 (ko) 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
CN102791258B (zh) 雷沙吉兰的延长释放制剂及其用途
JP6902033B2 (ja) 発作−関連障害の処置のための方法および組成物
JP7323451B2 (ja) フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤
US20120177731A1 (en) Controlled release formulations of levodopa and uses thereof
JP6846343B2 (ja) 特に注意欠陥障害の治療のための方法および組成物
CN104902880B (zh) 包含氢吗啡酮和纳洛酮的药物组合物
JP5138932B2 (ja) モダフィニルの改変された放出の製薬学的組成物
US20130251803A1 (en) Once daily formulation of lacosamide
WO2011085188A1 (en) Pharmaceutical compositions comprising anti-psychotic drugs
WO2015063670A1 (en) Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
CN101031290B (zh) 改良释放的莫达非尼药物组合物
EP3184101A1 (en) Levodopa and carbidopa modified release composition
HK1089697B (en) Modafinil modified release pharmaceutical compositions
HK40044922A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070911

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080430

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120515

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121016

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees